Latest Patents News

Page 6 of 104
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Phoslock Environmental Technologies Limited (ASX:PET) reduced its September-quarter operating cash outflow to A$21,000 as sales receipts more than doubled from the previous quarter. The company has paused manufacturing in China after storage capacity was reached, while new lanthanum formulations and a first Phoslock 10 field trial move forward.
Maxwell Dee
Maxwell Dee
22 Oct 2026
Everest Metals has advanced its Mt Edon rubidium project towards pilot plant development after batch testing delivered recovery of up to 90% and cut leaching water use by 60%. The scale-up remains unfinished, with continuous rotary-kiln trials producing lower and variable recovery of 50% to 60%.
Maxwell Dee
Maxwell Dee
20 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Mount Ridley has lodged a second provisional patent application for an adapted Selectro chemistry targeting industrial metal feedstocks, following first-pass bauxite recoveries of 92% aluminium and 97% iron. Gallium results are still pending, and the process has not yet been optimised for bauxite.
Victor Sage
Victor Sage
19 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
Mount Ridley Mines says its patent-pending Selectro process recovered 91.9% of aluminium and 96.7% of iron from a third-party bauxite sample at below 100°C. The test produced a small, pH-neutral silica-rich residue instead of conventional red mud, but product purification, economics and scale-up remain unproven.
Victor Sage
Victor Sage
15 Oct 2026
49 Metals says every hole in its maiden Gold Mountain campaign intersected gold or silver, including a high-grade 27.4-metre interval and a 170.7-metre broad intercept. A second drilling campaign is now testing whether the Adit Zone has the continuity and scale needed to support a maiden mineral resource estimate in 2027.
Maxwell Dee
Maxwell Dee
14 Oct 2026
Talga has moved Talnode-C from qualification into commercial shipments, completed key engineering work for its staged Vittangi project and secured major Swedish permits. But the battery materials developer remains loss-making, cash-burning and reliant on further funding to continue development.
Victor Sage
Victor Sage
14 Oct 2026
Perpetual Resources and adviser GreenMet are assessing several US Government funding and financing pathways for the Nevada Scheelite tungsten project, as Washington prepares tighter defence sourcing rules. The interest is strategic, but no funding has been secured and the project remains without a Mineral Resource or Ore Reserve.
Maxwell Dee
Maxwell Dee
13 Oct 2026
Cynata Therapeutics has lodged a replacement prospectus for a fully underwritten $913,000 entitlement offer, with the cash earmarked largely for adviser costs, intellectual property maintenance and working capital. The raising gives the biotech a near-term funding bridge, but the prospectus again flags a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
12 Oct 2026

Browse the archive

Full archive